Form 4: Tyra Biosciences Officer Hiroomi Tada Reports Stock Acquisition Under Employee Stock Purchase Plan
SEC Form 4 Filing
Hiroomi Tada, Chief Medical Officer of Tyra Biosciences, acquired 1,968 shares of common stock through the company's Employee Stock Purchase Plan on March 15, 2024.
Summary
- On March 15, 2024, Hiroomi Tada, the Chief Medical Officer of Tyra Biosciences, acquired 1,968 shares of common stock.
- The acquisition was made through the company's 2021 Employee Stock Purchase Plan.
- The price per share was $6.579.
- Following the transaction, Tada directly owns 86,435 shares of Tyra Biosciences.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a routine transaction. The acquisition of shares by an officer could be interpreted slightly positively, but it's primarily an informational document.
Positives
- The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to insider trading and is a common occurrence for publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, primarily providing transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of stock acquisition by Hiroomi Tada |
| 03/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.